392 A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma

Схожі ресурси

• Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
  за авторством: Mark Voskoboynik, та інші
  Опубліковано: (2024-08-01)
• S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES
  за авторством: Stacey Dillon, та інші
  Опубліковано: (2023-08-01)
• First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects
  за авторством: Jing Yang, та інші
  Опубліковано: (2021-07-01)
• PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
  за авторством: Catherine M Broome, та інші
  Опубліковано: (2023-08-01)
• Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
  Опубліковано: (2024-10-01)